Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Dontcho Jelev"'
Autor:
Zehua Sun, Xiaojie Chu, Cynthia Adams, Tatiana V. Ilina, Michel Guerrero, Guowu Lin, Chuan Chen, Dontcho Jelev, Rieko Ishima, Wei Li, John W. Mellors, Guillermo Calero, Dimiter S. Dimitrov
Publikováno v:
Molecular Therapy: Oncolytics, Vol 31, Iss , Pp 100726- (2023)
Mesothelin (MSLN) has been a validated tumor-associated antigen target for several solid tumors for over a decade, making it an attractive option for therapeutic interventions. Novel antibodies with high affinity and better therapeutic properties are
Externí odkaz:
https://doaj.org/article/e3ac5eca01cc47a6b9a22161f0b5c4b7
Autor:
Guillem Pascual-Pasto, Brendan McIntyre, Rawan Shraim, Samantha Buongervino, Amy Erbe, Dontcho Jelev, Anna Giudice, Daniel Martinez, Laura Garcia-Gerique, Dimiter Dimitrov, Paul Sondel, Kristopher Bosse
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Zehua Sun, Xiaojie Chu, Cynthia Adams, Tatiana V. Ilina, Michel Guerrero, Guowu Lin, Chuan Chen, Dontcho Jelev, Rieko Ishima, Wei Li, John W Mellors, Guillermo Calero, Dimiter S Dimitrov
Antibody based therapeutics targeting mesothelin (MSLN) have shown limited anticancer activity in clinical trials. Novel antibodies with high affinity and better therapeutic properties are needed. In the current study, we have isolated and characteri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ad153397cd3131a1b196e2a22ff7e4a
https://doi.org/10.1101/2022.04.07.487497
https://doi.org/10.1101/2022.04.07.487497
Autor:
Jose G. Vilches-Moure, Hima Anbunathan, Ansuman T. Satpathy, Zhongyu Zhu, Dorota Klysz, Kevin R. Parker, Peng Xu, Elena Sotillo-Pineiro, Samantha Buongervino, Alberto Delaidelli, Johanna Theruvath, Dimiter S. Dimitrov, Crystal L. Mackall, Sabine Heitzeneder, Dontcho Jelev, Anya Alag, Jennifer Hwang, John M. Maris, Shaurya Dhingra, Kristopher R. Bosse, Jing Huang, Poul H. Sorensen, Martin Hasselblatt, Robbie G. Majzner, Min Huang
Publikováno v:
Cancer Research. 81:1548-1548
Background: CAR T-cells targeting solid tumor antigens have not yet demonstrated similar success as seen for CD19, BCMA and CD22 in B-cell malignancies. Truly tumor-specific antigens are rare, yet pediatric solid tumors manifest stalled fetal develop